Loading clinical trials...
Loading clinical trials...
Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)
Conditions
Interventions
Ranibizumab 0.5mg
Locations
2
United States
NJ Retina (Retina Associates of New Jersey)
Teaneck, New Jersey, United States
NJ Retina (Retina Associates of New Jersey)
Vauxhall, New Jersey, United States
Start Date
May 1, 2015
Primary Completion Date
July 1, 2018
Completion Date
July 1, 2018
Last Updated
August 28, 2018
NCT05913063
NCT06990269
NCT06970665
NCT07160179
NCT06557460
NCT05562947
Lead Sponsor
Leonard Feiner, MD, PhD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions